BRPI1013387A2 - biomarcadores relacionados à resistência à insulina e métodos de uso dos mesmos - Google Patents

biomarcadores relacionados à resistência à insulina e métodos de uso dos mesmos

Info

Publication number
BRPI1013387A2
BRPI1013387A2 BRPI1013387-9A BRPI1013387A BRPI1013387A2 BR PI1013387 A2 BRPI1013387 A2 BR PI1013387A2 BR PI1013387 A BRPI1013387 A BR PI1013387A BR PI1013387 A2 BRPI1013387 A2 BR PI1013387A2
Authority
BR
Brazil
Prior art keywords
content item
wcd
marker
service provider
content
Prior art date
Application number
BRPI1013387-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Fu Hu Yun
Chirila Costel
Alexander Danny
Milburn Michael
W. Mitchell Matthew
Gall Walter
A. Lawton Kay
Original Assignee
Metabolon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolon, Inc. filed Critical Metabolon, Inc.
Publication of BRPI1013387A2 publication Critical patent/BRPI1013387A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1013387-9A 2009-03-31 2010-03-31 biomarcadores relacionados à resistência à insulina e métodos de uso dos mesmos BRPI1013387A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16533609P 2009-03-31 2009-03-31
US61/165,336 2009-03-31
US16657209P 2009-04-03 2009-04-03
US61/166,572 2009-04-03
PCT/US2010/029399 WO2010114897A1 (en) 2009-03-31 2010-03-31 Biomarkers related to insulin resistance and methods using the same

Publications (1)

Publication Number Publication Date
BRPI1013387A2 true BRPI1013387A2 (pt) 2019-04-16

Family

ID=42828685

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013387-9A BRPI1013387A2 (pt) 2009-03-31 2010-03-31 biomarcadores relacionados à resistência à insulina e métodos de uso dos mesmos

Country Status (6)

Country Link
US (1) US20120122981A1 (enExample)
EP (1) EP2414535A4 (enExample)
JP (1) JP2012522989A (enExample)
CN (1) CN102449161A (enExample)
BR (1) BRPI1013387A2 (enExample)
WO (1) WO2010114897A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172775A4 (en) * 2007-06-25 2010-12-01 Ajinomoto Kk METHOD OF EVALUATING VISCERAL GREASE ACCUMULATION
BRPI0815095B1 (pt) * 2007-07-17 2021-04-13 Metabolon, Inc Método de classificação de um indivíduo de acordo com a tolerância à glicose predita em tolerância à glicose normal (ngt), tolerância à glicose de jejum prejudicada (ifg), ou tolerância à glicose prejudicada (igt), para diabetes tipo 2, método de determinação da suscetibilidade de um indivíduo a diabetes tipo 2 e método de monitoramento da progressão ou regressão do pré- diabetes em um indivíduo
US10215765B2 (en) 2010-09-15 2019-02-26 Quest Diagnostics Investments Incorporated Detection of vitamins A and E by tandem mass spectrometry
WO2012058298A1 (en) * 2010-10-26 2012-05-03 Mayo Foundation For Medical Education And Research Biomarkers of reduced insulin action
KR101303825B1 (ko) * 2011-06-02 2013-09-05 연세대학교 산학협력단 혈장 대사체를 이용한 제2형 당뇨병 진단 키트
JP6260275B2 (ja) 2011-06-30 2018-01-17 味の素株式会社 脂肪肝の評価方法、脂肪肝評価装置、脂肪肝評価方法、脂肪肝評価プログラム、脂肪肝評価システム、および端末装置
JP6158186B2 (ja) * 2011-09-14 2017-07-05 メタボロン，インコーポレイテッド インスリン抵抗性に関連するバイオマーカーおよびそれを使用する方法
EP2642295A1 (en) * 2012-03-22 2013-09-25 Nestec S.A. 1-O-alkyl-2-acylglycerophosphocholine (PC-O) 40:1 as biomarker for healthy ageing
EP2642293A1 (en) 2012-03-22 2013-09-25 Nestec S.A. 9-oxo-octadecadienoic acid (9-oxo-HODE)as as biomarker for healthy ageing
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
US9470771B2 (en) 2012-06-08 2016-10-18 Liposcience, Inc. NMR measurements of NMR biomarker GlycA
US9361429B2 (en) * 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
WO2014026991A1 (en) * 2012-08-13 2014-02-20 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Biomarkers for type 2 diabetes
US20140324460A1 (en) * 2012-09-26 2014-10-30 Health Diagnostic Laboratory, Inc. Method for determining and managing total cardiodiabetes risk
WO2014105858A1 (en) 2012-12-26 2014-07-03 Quest Diagnostics Investments Incorporated C peptide detection by mass spectrometry
US10191032B2 (en) 2013-01-11 2019-01-29 True Health Ip Llc Method of detection and treatment of clinically significant post-prandial hyperglycemia in normoglycemic patients
WO2014120449A1 (en) * 2013-01-31 2014-08-07 Metabolon, Inc. Biomarkers related to insulin resistance progression and methods using the same
US20140278121A1 (en) * 2013-03-13 2014-09-18 Robust for Life, Inc. Systems and methods for network-based calculation and reporting of metabolic risk
US10772554B2 (en) * 2013-09-04 2020-09-15 Joseph Michael Lawless Kelly Methods and systems for the detection of disease
AU2015243857A1 (en) * 2014-04-08 2016-10-20 Metabolon, Inc. Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
JP6051258B2 (ja) * 2015-04-15 2016-12-27 ライオン株式会社 脂質異常症への罹患しやすさを試験する方法
JP6051257B2 (ja) * 2015-04-15 2016-12-27 ライオン株式会社 脂質異常症への罹患しやすさを試験する方法
JP6873490B2 (ja) * 2015-10-18 2021-05-19 ジア，ウェイ 糖尿病関連バイオマーカーおよび糖尿病関連状態の処置
GB201522302D0 (en) 2015-12-17 2016-02-03 Mars Inc Food product for regulating lipid metabolites
CN106093430A (zh) * 2016-06-06 2016-11-09 上海阿趣生物科技有限公司 可用于检测糖尿病的标志物及其用途
CN108318573B (zh) * 2016-08-16 2020-11-13 北京毅新博创生物科技有限公司 检测胰岛素抵抗的质谱模型的制备方法
CN106442770B (zh) * 2016-09-05 2019-01-18 南京医科大学 与特发性男性不育相关的精浆代谢小分子标志物及其检测方法和应用
CN106908605B (zh) * 2017-01-22 2019-02-22 中国人民解放军军事医学科学院基础医学研究所 eLtaS蛋白作为预防和治疗胰岛素抵抗相关疾病的药物靶点的应用
JP7197555B2 (ja) * 2017-08-17 2022-12-27 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 思春期前の小児期前糖尿病のマーカー
CN108623655B (zh) * 2018-05-15 2020-09-01 浙江省农业科学院 改善胰岛素抵抗的二肽el及其用途
CN109298084A (zh) * 2018-07-23 2019-02-01 上海市东方医院 用于检测血清或者血浆中油酸浓度的试剂盒及其制备方法和应用
US20210396766A1 (en) * 2018-09-27 2021-12-23 Societe Des Produits Nestle S.A. Markers of risk to develop insulin resistance during childhood and young adulthood
CN110887808A (zh) * 2019-10-28 2020-03-17 广东省测试分析研究所（中国广州分析测试中心） 一种红外光谱技术快速检测阿卡波糖发酵过程中的糖源含量的方法
CN112903885B (zh) * 2019-12-03 2022-05-06 中国科学院大连化学物理研究所 一种筛查糖尿病的联合型代谢标志物的应用及其试剂盒
CN213980949U (zh) 2020-08-27 2021-08-17 康明斯电力公司 用于发电机组的系统
CN112461986B (zh) * 2021-02-03 2021-06-08 首都医科大学附属北京友谊医院 一种用于评估空腹血糖受损和2型糖尿病患病风险的整合生物标志物体系
EP3922990B1 (en) 2021-03-28 2024-05-08 MS Ekspert Sp. z o.o. System for automatic changing and sealing of disposable chromatographic columns in high-performance liquid chromatography; measurement method and its application in the analysis of biomarker of rare disease
CN113929762B (zh) * 2021-12-16 2022-04-26 清华大学 3-羟基丁酰化和/或3-羟基戊酰化修饰胰岛素及其应用
CN117159717A (zh) * 2023-09-28 2023-12-05 广东省人民医院 Slc25a33在制备预防或治疗葡萄糖代谢相关疾病的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0825258A4 (en) * 1996-02-20 2001-12-05 Kyowa Hakko Kogyo Kk METHOD OF DETERMINING 1,5-ANHYDROGLUCITOL
US20030092028A1 (en) * 2001-06-01 2003-05-15 Yuanhong Ma Methods and Reagents For Diagnosis and Treatment of Insulin Resistance and Related Condition
US7425545B2 (en) * 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
EP2126589A4 (en) * 2007-02-22 2011-06-08 Lipomics Technologies Inc METABOLISM AND DIABETIC SUFFERING AND METHOD OF USE THEREOF
BRPI0815095B1 (pt) * 2007-07-17 2021-04-13 Metabolon, Inc Método de classificação de um indivíduo de acordo com a tolerância à glicose predita em tolerância à glicose normal (ngt), tolerância à glicose de jejum prejudicada (ifg), ou tolerância à glicose prejudicada (igt), para diabetes tipo 2, método de determinação da suscetibilidade de um indivíduo a diabetes tipo 2 e método de monitoramento da progressão ou regressão do pré- diabetes em um indivíduo

Also Published As

Publication number Publication date
EP2414535A1 (en) 2012-02-08
EP2414535A4 (en) 2012-12-26
JP2012522989A (ja) 2012-09-27
US20120122981A1 (en) 2012-05-17
CN102449161A (zh) 2012-05-09
WO2010114897A1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
BRPI1013387A2 (pt) biomarcadores relacionados à resistência à insulina e métodos de uso dos mesmos
BRPI1016087A2 (pt) método e equipamento para habilitar interação sensível a contexto com conteúdo distribuído
BR112012029675A2 (pt) aparelho e sistema de processamento de informação, e, programa
BR112013002305A2 (pt) método, sistema e dispositivo para agregação de rede de rádio
BR112013020739A2 (pt) um sistema e método para obter dados de rede
AR064022A1 (es) Un metodo y dispositivo de navegacion que utilizacion un mensaje de ubicacion
WO2009004701A1 (ja) ネットワーク障害検知システム、計測エージェント、監視サーバ、ネットワーク障害検知方法およびネットワーク障害検知プログラム
BR112014012930A2 (pt) método para um primeiro dispositivo para comunicar-se com um segundo dispositivo em uma rede sem fio, produto de programa de computador, dispositivo para a comunicação com outro dispositivo em uma rede sem fio, e sistema para comunicações sem fio
BR112019002369A2 (pt) método para relatar estado de canal em sistema de comunicação sem fio, e dispositivo para isso
WO2008111049A3 (en) System and method for a virtual hosted operating system
BR112015014999A2 (pt) sistema e aparelho para cuidados com pacientes com elementos eletrônicos
BR112013003356A2 (pt) métodos e aparelhos para ativar medições de localização
BR112012009720A2 (pt) servidor que fornece um serviço de upload de conteúdo, método para fazer upload de conteúdo de um servidor, terminal para fazer upload de conteúdo, e método para fazer o upload de conteúdo de um terminal
BR112014007682A2 (pt) método de indicação de medição de interferência, método de medição de interferência, dispositivo relacionado e sistema de comunicação
BR112016002006A2 (pt) método e aparelho e sistema de configuração de rede
BRPI1010808A2 (pt) "método e sistema implementado por computador para postar conteúdo com acessibilidade seletiva e método de gestão de comunicação de conteúdo em serviço de rede social"
EP2838230A3 (en) Scalable policy-controlled packet inspection systems and methods for advanced application interface
BR112012007188A2 (pt) método para configurar um equipamento de usuário, método configurado para ser transferido de uma estação base fonte para uma estação base alvo em um cenário de transferência, estação base, e, equipamento de usuário
BRPI1013175A2 (pt) sistema para uso com um provedor de serviço e um dispositivo eletrônico de consumidor, método para uso com um dispositivo eletrônico de consumidor e um provedor de serviço, e, produto de programa de computador.
BR112014020214A8 (pt) Método para habilitar a comunicação em rede com um dispositivo eletrônico inteligente, sistema para gerenciar a comunicação em rede com um dispositivo eletrônico inteligente, controlador de acesso, e, mídia legível
MX2010013081A (es) Sistema y metodo para manejar solicitudes de emergencia.
BR112014010191A8 (pt) método, aparelho e sistema para permitir a recuperação do conteúdo de interesse para revisão subsequente
BR112013027005A2 (pt) método e sistema para compartilhar e utilizar informação de localização em um terminal portátil
BR112014004966A2 (pt) método e sistema para provisionar informação atualizada
GB0803273D0 (en) System, method and computer program for modifying communications

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]